Patents by Inventor Vincenzo Cerullo
Vincenzo Cerullo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230321209Abstract: The invention concerns a modified bacteria; a pharmaceutical composition comprising same; and a method of preventing or treating disease particularly, but not exclusively, cancer or an infectious disease using same.Type: ApplicationFiled: August 27, 2021Publication date: October 12, 2023Applicant: Valo Therapeutics OyInventors: Erkko Ylösmäki, Manlio Fusciello, Beatriz Martins, Sara Feola, Jacopo Chiaro, Vincenzo Cerullo
-
Publication number: 20230266307Abstract: The invention concerns a device for tumour antigen identification and a method for tumour antigen identification; a tumour antigen identified following use of said device and/or method; a pharmaceutical composition comprising said tumour antigen; a method of treating cancer using said device and/or said method; a method of stratifying patients for cancer treatment using said device and/or said method; a treatment regimen involving stratifying patients for cancer treatment using said device and/or method and then administering a cancer therapeutic; and a tumour antigen identified using said device and/or said method for use as a cancer vaccine or immunogenic agent or cancer therapy.Type: ApplicationFiled: May 6, 2021Publication date: August 24, 2023Applicant: University of HelsinkiInventors: Vincenzo Cerullo, Cristian Capasso, Tiina Sikanen, Sara Feola, Sari Tahka, Jacopo Chiaro
-
Patent number: 11730798Abstract: The present invention relates to adenoviral vectors, wherein the viral capsid has been coated with polypeptides, which are capable of stimulating a peptide-specific immune response in a subject and uses thereof. Furthermore, the present invention relates to methods of treating diseases, e.g. cancer, by adenoviral vectors which have been coated by polypeptides causing peptide-specific immune response. Also the present invention relates to a method of coating adenoviral vectors by specific peptides as well as to a method of identifying those peptides suitable for coating the capsid of an adenoviral vector.Type: GrantFiled: September 2, 2020Date of Patent: August 22, 2023Assignee: Valo Therapeutics OyInventors: Vincenzo Cerullo, Markus Vähä-Koskela, Mari Hirvinen, Cristian Capasso
-
Publication number: 20230062122Abstract: The present invention relates to adenoviral vectors, wherein the viral capsid has been coated with polypeptides, which are capable of stimulating a peptide-specific immune response in a subject and uses thereof (e.g. infectious disease). Furthermore, the present invention relates to methods of treating diseases, e.g., cancer or an infectious disease, by adenoviral vectors which have been coated by polypeptides causing peptide-specific immune response. Also the present invention relates to a method of coating adenoviral vectors by specific peptides as well as to a method of identifying those peptides suitable for coating the capsid of an adenoviral vector.Type: ApplicationFiled: September 13, 2022Publication date: March 2, 2023Inventors: Vincenzo Cerullo, Markus Vähä-Koskela, Mari Hirvinen, Cristian Capasso, Sari Pesonen, Leena Ylösmäki, Lukasz Kuryk
-
Publication number: 20220288184Abstract: The invention concerns a novel viral vector with modified viral capsid or viral envelope; a pharmaceutical composition or immunogenic agent or vaccine comprising same; a target cell transformed or transfected with same; a combination therapeutic comprising same; use of same in treatment of cancer, and a method of treating cancer using same.Type: ApplicationFiled: May 21, 2020Publication date: September 15, 2022Applicant: Valo Therapeutics OyInventors: Vincenzo Cerullo, Cristian Capasso, Sara Feola, Siri Tahtinen
-
Publication number: 20210332382Abstract: The invention concerns a modified oncolytic adenovirus; a pharmaceutical composition comprising same; and a method of treating cancer using same.Type: ApplicationFiled: March 19, 2019Publication date: October 28, 2021Applicant: Valo Therapeutics OyInventors: Tuuli Ranki, Sari Pesonen, Petri Priha, Erkko Ylösmäki, Vincenzo Cerullo, Beatriz Martins
-
Patent number: 10982194Abstract: The invention concerns a modified enveloped virus wherein said virus has at least one anti-tumor, tumor-specific peptide non-genetically attached to or inserted in/through the viral envelope; a pharmaceutical composition comprising same; and a method of treating cancer using same.Type: GrantFiled: September 6, 2017Date of Patent: April 20, 2021Assignee: VALO THERAPEUTICS OYInventors: Vincenzo Cerullo, Cristian Capasso, Erkko Ylosmaki
-
Publication number: 20210100883Abstract: The present invention relates to adenoviral vectors, wherein the viral capsid has been coated with polypeptides, which are capable of stimulating a peptide-specific immune response in a subject and uses thereof. Furthermore, the present invention relates to methods of treating diseases, e.g. cancer, by adenoviral vectors which have been coated by polypeptides causing peptide-specific immune response. Also the present invention relates to a method of coating adenoviral vectors by specific peptides as well as to a method of identifying those peptides suitable for coating the capsid of an adenoviral vector.Type: ApplicationFiled: September 2, 2020Publication date: April 8, 2021Inventors: Vincenzo Cerullo, Markus Vähä-Koskela, Mari Hirvinen, Cristian Capasso
-
Publication number: 20210017501Abstract: The invention concerns a modified replication competent, oncolytic adenovirus; a pharmaceutical composition comprising same; and a method of treating cancer using same.Type: ApplicationFiled: March 19, 2019Publication date: January 21, 2021Applicant: Valo Therapeutics OyInventors: Tuuli Ranki, Sari Pesonen, Petri Priha, Erkko Ylösmäki, Vincenzo Cerullo, Beatriz Martins
-
Publication number: 20200399615Abstract: The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to oncolytic adenoviral vectors alone or together with therapeutic compositions for therapeutic uses and therapeutic methods for cancer. In one aspect the present invention relates to separate administration of adoptive cell therapeutic composition and oncolytic adenoviral vectors. Furthermore, the present invention relates to a pharmaceutical kit and a pharmaceutical composition, both utilizing oncolytic adenoviral vectors.Type: ApplicationFiled: September 2, 2020Publication date: December 24, 2020Inventors: Akseli Hemminki, Markus Vähä-Koskela, Siri Tähtinen, Vincenzo Cerullo
-
Patent number: 10799568Abstract: The present invention relates to adenoviral vectors, wherein the viral capsid has been coated with polypeptides, which are capable of stimulating a peptide-specific immune response in a subject and uses thereof. Furthermore, the present invention relates to methods of treating diseases, e.g. cancer, by adenoviral vectors which have been coated by polypeptides causing peptide-specific immune response. Also the present invention relates to a method of coating adenoviral vectors by specific peptides as well as to a method of identifying those peptides suitable for coating the capsid of an adenoviral vector.Type: GrantFiled: May 18, 2015Date of Patent: October 13, 2020Assignee: VALO THERAPEUTICS OYInventors: Vincenzo Cerullo, Markus Vähä-Koskela, Mari Hirvinen, Cristian Capasso
-
Patent number: 10787645Abstract: The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to oncolytic adenoviral vectors alone or together with therapeutic compositions for therapeutic uses and therapeutic methods for cancer. In one aspect the present invention relates to separate administration of adoptive cell therapeutic composition and oncolytic adenoviral vectors. Furthermore, the present invention relates to a pharmaceutical kit and a pharmaceutical composition, both utilizing oncolytic adenoviral vectors.Type: GrantFiled: November 15, 2016Date of Patent: September 29, 2020Assignee: TILT Biotherapeutics OyInventors: Akseli Hemminki, Markus Vähä-Koskela, Siri Tähtinen, Vincenzo Cerullo
-
Patent number: 10647963Abstract: The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to oncolytic adenoviral vectors alone or together with therapeutic compositions for therapeutic uses and therapeutic methods for cancer. In one aspect the present invention relates to separate administration of adoptive cell therapeutic composition and oncolytic adenoviral vectors. Furthermore, the present invention relates to a pharmaceutical kit and a pharmaceutical composition, both utilizing oncolytic adenoviral vectors.Type: GrantFiled: April 16, 2014Date of Patent: May 12, 2020Assignee: TILT BIOTHERAPEUTICS OYInventors: Akseli Hemminki, Markus Vaha-Koskela, Siri Tahtinen, Vincenzo Cerullo
-
Publication number: 20200010811Abstract: The invention concerns a modified enveloped virus wherein said virus has at least one anti-tumor, tumor-specific peptide non-genetically attached to or inserted in/through the viral envelope; a pharmaceutical composition comprising same; and a method of treating cancer using same.Type: ApplicationFiled: September 6, 2017Publication date: January 9, 2020Applicant: VALO THERAPEUTICS OYInventors: Vincenzo Cerullo, Cristian Capasso, Erkko Ylosmaki
-
Publication number: 20170137786Abstract: The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to oncolytic adenoviral vectors alone or together with therapeutic compositions for therapeutic uses and therapeutic methods for cancer. In one aspect the present invention relates to separate administration of adoptive cell therapeutic composition and oncolytic adenoviral vectors. Furthermore, the present invention relates to a pharmaceutical kit and a pharmaceutical composition, both utilizing oncolytic adenoviral vectors.Type: ApplicationFiled: November 15, 2016Publication date: May 18, 2017Inventors: Akseli Hemminki, Markus Vähä-Koskela, Siri Tähtinen, Vincenzo Cerullo
-
Publication number: 20170080069Abstract: The present invention relates to adenoviral vectors, wherein the viral capsid has been coated with polypeptides, which are capable of stimulating a peptide-specific immune response in a subject and uses thereof. Furthermore, the present invention relates to methods of treating diseases, e.g. cancer, by adenoviral vectors which have been coated by polypeptides causing peptide-specific immune response. Also the present invention relates to a method of coating adenoviral vectors by specific peptides as well as to a method of identifying those peptides suitable for coating the capsid of an adenoviral vector.Type: ApplicationFiled: May 18, 2015Publication date: March 23, 2017Inventors: Vincenzo Cerullo, Markus Vähä-Koskela, Mari Hirvinen, Cristian Capasso
-
Patent number: 9410129Abstract: The invention relates to oncolytic adenovirus vectors and their uses in cancer therapy. The adenovirus vectors according to the invention have superior safety properties and have effective therapeutic activity. A production method for the inventive adenoviruses is also disclosed. The adenovirus vectors are useful in cancer therapy.Type: GrantFiled: November 23, 2012Date of Patent: August 9, 2016Assignee: Targovax OyInventors: Tuuli Ranki, Akseli Hemminki, Vincenzo Cerullo, Anniina Koski
-
Publication number: 20160208287Abstract: The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies. More specifically, the present invention relates to oncolytic adenoviral vectors and cells and pharmaceutical compositions comprising said vectors. The present invention also relates to a use of said vectors in the manufacture of a medicament for treating cancer in a subject and a method of treating cancer in a subject. Furthermore, the present invention relates to methods of producing GM-CSF in a cell and increasing tumor specific immune response in a subject, as well as uses of the oncolytic adenoviral vector of the invention for producing GM-CSF in a cell and increasing tumor specific immune response in a subject.Type: ApplicationFiled: March 21, 2016Publication date: July 21, 2016Inventors: Akseli Hemminki, Anna Kanerva, Vincenzo Cerullo, Sari Pesonen
-
Patent number: 9345787Abstract: The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies. More specifically, the present invention relates to oncolytic adenoviral vectors and cells and pharmaceutical compositions comprising said vectors. The present invention also relates to a use of said vectors in the manufacture of a medicament for treating cancer in a subject and a method of treating cancer in a subject. Furthermore, the present invention relates to methods of producing GM-CSF in a cell and increasing tumor specific immune response in a subject, as well as uses of the oncolytic adenoviral vector of the invention for producing GM-CSF in a cell and increasing tumor specific immune response in a subject.Type: GrantFiled: December 21, 2009Date of Patent: May 24, 2016Assignee: Targovax OyInventors: Akseli Hemminki, Anna Kanerva, Vincenzo Cerullo, Sari Pesonen
-
Publication number: 20160082100Abstract: The invention relates to oncolytic adenovirus vectors and their uses in cancer therapy. The adenovirus vectors according to the invention have superior safety properties and have effective therapeutic activity. A production method for the inventive adenoviruses is also disclosed. The adenovirus vectors are useful in cancer therapy.Type: ApplicationFiled: September 25, 2015Publication date: March 24, 2016Inventors: Tuuli RANKI, Akseli HEMMINKI, Vincenzo CERULLO, Anniina KOSKI